trial
as of 2026-07-0118F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
NCTId NCT06880328
at a glance
Phase 1 · Completed
Enrollment 35 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2019-09-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2018-11-07
Primary completion
2019-09-04
Eligibility
MALE · 18 Years · 50 Years
Interventions & indications
Sponsors
Hoffmann-La RocheLead Sponsor
Sites
4 total
Glendale, United StatesTorrance, United StatesGaithersburg, United StatesSt Louis, United States
Facts & assertions
4 sourced
Enrollment
35
Phase
PHASE1
Primary Completion Date
2019-09-04
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication